KRAS and colorectal cancer: Indeed, numerous preclinical studies have shown that KRAS G12C inhibitors can at least partially reverse the KRAS-mediated immunosuppressive mechanisms described above and cause a profound remodeling of the TME in KRAS G12C-mutant lung and colorectal cancer (Fig. 2; refs. 12, 31, 54, 55).